In:
FEBS Letters, Wiley, Vol. 592, No. 4 ( 2018-02), p. 599-609
Abstract:
Although colorectal cancer ( CRC ) is a prevalent malignancy of the digestive system, the underlying mechanisms of CRC tumorigenesis are still elusive. Arrestin‐related domain‐containing protein‐3 ( ARRDC 3) has been reported to promote lysosome‐mediated protein degradation. In the present study, we find that the expression of ARRDC 3 is downregulated in CRC specimens. Mechanistically, we reveal that ARRDC 3 binds and decreases expression of the oncoprotein YAP , the cotranscription factor of the Hippo pathway. The regulation of the Hippo pathway by ARRDC 3 is conserved from Drosophila to mammals. Furthermore, we demonstrate that ARRDC 3 plays an anti‐oncogenic role in CRC progression by promoting YAP degradation. Finally, we show that ARRDC 3 increases the sensitivity of CRC cells toward chemotherapeutic drugs. Taken together, our findings point to ARRDC 3 as a potential target for CRC treatment.
Type of Medium:
Online Resource
ISSN:
0014-5793
,
1873-3468
DOI:
10.1002/feb2.2018.592.issue-4
DOI:
10.1002/1873-3468.12986
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
1460391-3
SSG:
12
Bookmarklink